AEON - AEON Biopharma Inc. Price-to-Projected Revenue Ratio

AEON Biopharma is developing alternatives to popular neurotoxins for the treatment of migraine and gastroparesis. The robotization of filling lines minimizes human error, radically increasing production sterility. Management is currently adapting the R&D strategy based on the results of recent tests. The company's forward P/S trend clearly demonstrates a market revaluation of the asset, where the metric value of captures current investor expectations.

AEON Bio - AEON Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for aeonbiopharma.com (AEON)

- market price and analyst price targets:

Price Chart AEON Biopharma, Inc.|AEON - Price Target Chart

- market capitalization statistics:

Market Value AEON Biopharma|AEON - Total Enterprise Value

- book value of equity indicators:

Book Value per Share AEON Biopharma|AEON - Book Value of Business|Market Cap to Net Assets Ratio aeonbiopharma.com|AEON - Company Assets

- debt and liquidity data:

- financial results and valuation multiples details:

AEON - Final Profit|Projected Future Earnings AEON Biopharma|AEON - Price to Earnings Ratio|Forward P/E Multiple AEON Biopharma, Inc.|AEON - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AEON Biopharma|AEON - Profit before interest, taxes and amortization|Earnings per share for the last twelve months AEON Biopharma|AEON - Earnings per one share for the last 12 months|Quarterly EPS earnings growth aeonbiopharma.com|AEON - Earnings per share increase in current year|Earnings growth forecast for next year AEON Biopharma

- revenue and sales proceeds data:

AEON - Revenue and Sales Volume|Company Projected Revenue AEON Biopharma, Inc.|AEON - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio AEON Biopharma

Initial company analysis:AEON (AEON Bio)

The forward P/S reflects the ratio of market capitalization to projected revenue, allowing for an assessment of the premium paid per unit of future sales at the level. High physician confidence in the ABP-450 drug stabilizes cash flows; therefore, any sharp deviations in the forward P/S indicator will signal an imbalance between market expectations and the actual asset value of AEON Biopharma (AEON).

Competitor analysis

Price-to-Projected Revenue Ratio Jazz Pharmaceuticals plc JAZZ|Cytokinetics Inc. - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Scholar Rock Inc.|CNTA: Forward P/S Multiple|Projected Price to Revenue dyne-tx.com DYN|Forward Price-to-Revenue Multiple EWTX|Market Cap to Future Revenue Ratio Rapport Therapeutics Inc RAPP|Forward P/S Multiple ALMS|Forward P/S Multiple Zevra Corp (ZVRA)|Forward P/S Multiple CTNM (Contineum Therapeutics, Inc.)|larimartx.com (LRMR) - Market Cap to Future Revenue Ratio|CAPR - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Entrada Therapeutics Inc.|Channel (PTHS) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue MNOV|Forward Price-to-Revenue Multiple SER|BTAI: Forward Price to Sales|Forward P/S Multiple PMN|Price-to-Projected Revenue Ratio APUS (apimedsus.com)|Forward P/S Multiple NLSP (NLS Pharmaceutics)|Market Cap to Expected Sales Ratio Bionomics Ltd. (BNOX)|HUGE - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio reatapharma.com